Search results
Results from the WOW.Com Content Network
Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.
David H. Raulet is an American immunologist who specializes in studying the role of natural killer cells.He is a professor in the Department of Molecular and Cell Biology at the University of California, Berkeley where he also holds the Esther and Wendy Schekman Chair in cancer biology. [1]
ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT 2A receptor agonist which is under development for the treatment of mood disorders and other psychiatric disorders. [1] [4] [5] [2] [3] In addition to acting at the serotonin 5-HT 2A receptor, it is also an antagonist of the serotonin 5-HT 2B receptor and an agonist of the serotonin 5-HT 2C receptor.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells.
News. Science & Tech. Shopping. Sports. Weather. US FDA approves Mesoblast's cell therapy for graft-versus-host disease. December 18, 2024 at 1:57 PM
News. Science & Tech. Shopping. Sports. Weather. Exclusive-US FDA finds widely used asthma drug impacts the brain. Dan Levine and Sheila Dang. November 22, 2024 at 6:03 AM. By Dan Levine and ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
GSK1360707F is a potent and selective triple reuptake inhibitor. [1] It is chemically related to amitifadine and NS-2359 (GSK-372,475). Until recently, [when?] it was under development for the treatment of major depressive disorder; its development was put on hold for strategic reasons.